<?xml version="1.0" encoding="UTF-8"?>
<ref id="B43-vaccines-08-00115">
 <label>43.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Donofrio</surname>
    <given-names>G.</given-names>
   </name>
   <name>
    <surname>Franceschi</surname>
    <given-names>V.</given-names>
   </name>
   <name>
    <surname>Capocefalo</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Taddei</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Sartori</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Bonomini</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Cavirani</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Cabassi</surname>
    <given-names>C.S.</given-names>
   </name>
   <name>
    <surname>Flammini</surname>
    <given-names>C.F.</given-names>
   </name>
  </person-group>
  <article-title>Cellular targeting of engineered heterologous antigens is a determinant factor for bovine herpesvirus 4-based vaccine vector development</article-title>
  <source>Clin. Vaccine. Immunol.</source>
  <year>2009</year>
  <volume>16</volume>
  <fpage>1675</fpage>
  <lpage>1686</lpage>
  <pub-id pub-id-type="doi">10.1128/CVI.00224-09</pub-id>
  <?supplied-pmid 19793901?>
  <pub-id pub-id-type="pmid">19793901</pub-id>
 </element-citation>
</ref>
